Clinical data | |
---|---|
Trade names | Xenpozyme |
Other names | GZ402665, olipudase alfa-rpcp |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
DrugBank |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C2900H4373N783O791S24 |
Molar mass | 63632.01 g·mol−1 |
Olipudase alfa, sold under the brand name Xenpozyme, is a medication used for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) type A/B or type B.[2][4][3][5]
The common side events include infections, infusion-related reactions, or gastrointestinal complaints (disease signs and symptoms in children).[5]
Historically referred to as Niemann-Pick disease types A (NPD A) and B (NPD B), ASMD is a genetic disorder.[3] It belongs to the larger family of metabolic disorders called lysosomal storage diseases, in which fats build up within the parts of the body's cells that break down nutrients and other materials.[3] This affects the way cells work and causes them to die, affecting normal functioning of tissues and organs.[3] ASMD is seriously debilitating and life-threatening since the build-up of fatty substances can cause brain damage and swelling of organs such as liver and spleen.[3]
Xenpozyme is the first ASMD-specific treatment.[3] This medicine is an enzyme replacement therapy, developed to replace patients' deficient or defective enzyme, acid sphingomyelinase (ASM), and thereby reduce fat accumulation within cells and relieve some of the symptoms of the disease.[3] Xenpozyme was approved by the European Medicines Agency for the treatment of Acid sphingomyelinase deficiency (ASMD) type A/B or type B,[6] and by the US Food and Drug Administration for the treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.[7] The replacement enzyme is produced by a method known as recombinant DNA technology: it is made by cells into which a gene (DNA) has been introduced, that enables them to produce the enzyme.[3]
Olipudase alfa was approved for medical use in Japan in March 2022,[4] in the European Union in June 2022,[3] and in the United States in August 2022.[2][8] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[9][10]